William Hagstrom

Bill has more than 25 years of start-up experience in a broad range of medical specialties intersecting science, technology, clinical medicine, and business strategy. Prior to founding Octave Bioscience, he served as the CEO of Crescendo Bioscience which created novel measurement tools and software in the field of rheumatology. Prior to this, he was the President of Alpha BioPartners, a strategic consulting firm advising the launch of new life sciences companies. While at Alpha BioPartners, Bill created the business plan for Crescendo and co-founded Altheus Therapeutics and Biolytx Pharmaceuticals. Prior to that, he served as the initial CEO of Selexys Pharmaceuticals and interim CEO of Inoveon in ophthalmology. In the 1990s, Bill was Chairman and CEO of UroCor, a urology specialty diagnostics company which he scaled from start-up through IPO. Earlier in his career, he was Vice President of Baxter International’s $1.0 billion Scientific Products Division and held management positions at the American Hospital Supply and Becton Dickinson. He currently serves on the board of directors for CareDx, Navican, Genalyte and CoFactor. Previously he was on the board of Prometheus Laboratories. Bill holds a BS in Business Management from Bob Jones University.